Welcome to our dedicated page for Mesa Laboratories news (Ticker: MLAB), a resource for investors and traders seeking the latest updates and insights on Mesa Laboratories stock.
Mesa Laboratories Inc. (NASDAQ: MLAB) is a prominent global entity dedicated to the development, manufacturing, and marketing of superior process validation, monitoring, and calibration instruments and consumables. The company plays a crucial role across numerous regulated applications in the pharmaceutical, healthcare, and medical device sectors, making it a vital player in ensuring product integrity, enhancing patient and worker safety, and elevating the overall quality of life.
Mesa Laboratories operates through four main divisions, each catering to specific industry needs:
- Sterilization and Disinfection Control: This division focuses on producing and selling biological, cleaning, and chemical indicators, alongside offering testing and laboratory services. Their products are indispensable in medical device and pharmaceutical manufacturing sterilization monitoring, including various sterilization methods like steam, EO, H2O2, and chlorine dioxide.
- Biopharmaceutical Development: Specializing in automated systems for protein analysis and peptide synthesis, this segment supports the critical needs of the biopharmaceutical sector, ensuring rigorous quality control and reliability.
- Calibration Solutions: Mesa's offerings in this division include high-quality data loggers for temperature, humidity, and pressure monitoring, as well as NIST-traceable calibration solutions for various parameters essential for health and safety compliance.
- Clinical Genomics: This division caters to the evolving needs of genomic testing and diagnostics, providing advanced solutions that uphold the highest standards of accuracy and reliability.
Among its notable products, Mesa's Phoenix meter and the 90XL meter stand out. The Phoenix meter is a point-of-use dialysate QC meter, whereas the 90XL meter serves as the industry benchmark for dialysis machine calibration.
Financially, Mesa has recently navigated several strategic moves, including the acquisition of GKE entities, which are projected to add significant revenue. Despite facing challenges like the economic slowdown in China impacting their Clinical Genomics division, Mesa has shown resilience with sequential revenue growth driven by their Calibration Solutions division.
Mesa's commitment to innovation and quality is further highlighted by their ongoing projects and partnerships intended to expand their product lines and market reach. The company is focused on leveraging synergies from acquisitions and refining their business strategy, particularly in their Clinical Genomics division, to adapt to regulatory changes and market demands.
For the latest updates and in-depth information about Mesa Laboratories Inc., visit their official website at www.mesalabs.com.
Mesa Laboratories (NASDAQ:MLAB) has declared a quarterly dividend of $0.16 per share, set to be paid on June 15, 2021, to shareholders recorded as of May 31, 2021. This decision reflects the company's commitment to returning value to shareholders. Mesa Labs focuses on providing essential quality control solutions across various industries, enhancing product integrity and worker safety.
Mesa Laboratories (NASDAQ:MLAB) reported financial results for 3Q21, revealing an 8% revenue increase to $34,172. Operating income rose significantly to $22 compared to a loss of $(3,255) in 3Q20. Despite this, net loss increased slightly to $(4,542) or $(0.89) per diluted share. Adjusted operating income surged by 162% to $7,461. Excluding unusual items, operating income dropped by 49%. The Sterilization and Disinfection Control division saw 13% growth. However, the Instruments division faced a 10% revenue decline, indicating mixed performance across segments.
Mesa Laboratories (NASDAQ:MLAB) announced a regular quarterly dividend of $0.16 per share, payable on March 15, 2021, to shareholders on record as of February 26, 2021. The company continues to lead in providing critical quality control solutions across various industries, including healthcare and pharmaceuticals. This dividend declaration reflects Mesa Labs' ongoing commitment to rewarding shareholders while maintaining its position as a trusted provider of quality control products and services.
Mesa Laboratories, Inc. (MLAB) reported a 25% increase in revenues for 2Q21, totaling $31,860, compared to the same period last year. However, operating income decreased by 5% to $4,470, and net income fell 16% to $2,679 ($0.51 per diluted share). Non-GAAP adjusted operating income rose by 41% to $9,990. The Sterilization and Disinfection Control division faced challenges, with a 4% decline in revenues. Conversely, the Biopharmaceutical Development division showed strong growth with a 53% sequential revenue increase. The company holds over $240 million in cash, positioning it for future growth opportunities.
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced a quarterly dividend of $0.16 per share, payable on December 15, 2020. Shareholders on record by November 30, 2020 will benefit from this distribution. Mesa Labs is a leader in quality control solutions across various sectors, including pharmaceuticals and healthcare. The company operates through four divisions, ensuring product integrity and improving safety. However, forward-looking statements mention risks related to demand fluctuations, competition, and COVID-19 impacts on operations.
Mesa Laboratories announced a 14% increase in revenue for Q1 2021, totaling $29,941 compared to the previous year. However, operating income fell 41% to $3,198 and net income dropped 78% to $1,025, equating to $0.22 per diluted share. The results were influenced by unusual items totaling $(364). Organic revenues declined 4% quarter-over-quarter, with the Sterilization division achieving 8% growth. Challenges remain in the Instruments and Biopharmaceutical Development divisions due to COVID-19 impacts, though the company maintains a strong financial position with $230,951 in cash.
Mesa Laboratories has declared a regular quarterly dividend of $0.16 per share, payable on September 15, 2020 to shareholders of record as of August 31, 2020. This payment reflects the company's commitment to returning value to shareholders. Mesa Labs operates in critical sectors like pharmaceuticals and healthcare, focusing on quality control solutions through its four divisions. Investors should note potential risks as the company navigates post-pandemic challenges and competition in the market.
Mesa Laboratories (NASDAQ: MLAB) announced the full exercise of underwriters' option to purchase 90,000 additional shares in its public offering, raising approximately $20.3 million. Combined with the initial offering proceeds, total gross proceeds reach about $155.3 million. The closing for the additional shares was completed on June 16, 2020. Mesa Labs plans to use the net proceeds for general corporate purposes, including potential acquisitions. The offering was conducted under its SEC shelf registration.
Mesa Laboratories, Inc. (NASDAQ: MLAB) announced the pricing of a public offering of 600,000 shares at $225.00 per share, aiming for gross proceeds of approximately $135 million. A 30-day option for underwriters to purchase an additional 90,000 shares is also granted. The offering, anticipated to settle on June 12, 2020, will fund general corporate purposes, including potential acquisitions. The offering is conducted under a shelf registration statement filed with the SEC.
Mesa Laboratories (NASDAQ: MLAB) announced a public offering of $100 million in common stock, with a potential additional $15 million option for underwriters. The offering is subject to market conditions and may not proceed as expected. The company plans to use the net proceeds for general corporate purposes, potentially including acquisitions. Jefferies LLC, J.P. Morgan, and Evercore Group are the joint book-running managers for the offering. Investors should review the prospectus filed with the SEC for detailed information.
FAQ
What is the current stock price of Mesa Laboratories (MLAB)?
What is the market cap of Mesa Laboratories (MLAB)?
What does Mesa Laboratories Inc. do?
What are the main divisions of Mesa Laboratories?
What are some notable products from Mesa Laboratories?
How has Mesa Laboratories performed financially recently?
What are Mesa Laboratories' recent strategic moves?
How does Mesa Laboratories ensure product integrity and safety?
What kind of services does the Biopharmaceutical Development division offer?
What impact did the acquisition of GKE have on Mesa Laboratories?
What has been the impact of the economic slowdown on Mesa Laboratories?
Where can I find more information about Mesa Laboratories Inc.?
